()
 
 

Overview

In August 2006, Infinity and MedImmune entered into an agreement to jointly develop and commercialize novel small molecule cancer drugs targeting Hsp90, including IPI-504 and IPI-493, as well as those targeting the Hedgehog cell signaling pathway, including IPI-926.


Contact Information

780 Memorial Drive
Cambridge, MA 02139

tel: 617-453-1000
fax: 617-453-1001
http://www.ipi.com

,  



Investor Relations



tel:
fax:




Stock

Exchange: NASDAQ
Industry: Diagnostic Substances
Market Cap: $151.9M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.